Abstract:Class I HDACs are considered promising targets for cancer due to their role in epigenetic modifications. The main challenges in developing a new, potent and non-toxic class I HDAC inhibitor are selectivity and appropriate pharmacokinetics. The PROTAC technique (Proteolysis Targeting Chimera) is a new method in drug development for the production of active substances that can degrade a protein of interest (POI) instead of inhibiting it. This technique will open the era to produce selective and potent drugs with a high margin of safety. Previously, we reported different inhibitors targeting class I HDACs functionalized with aminobenzamide or hydroxamate groups. In the current research work, we will employ PROTAC technique to develop class I HDAC degraders based on our previously reported inhibitors. We synthesized two series of aminobenzamide-based PROTACs and hydroxamate-based PROTACs and tested them in vitro against class I HDACs. To ensure their degradation, all of them were screened against HDAC2 as representative example of class I. The best candidates were evaluated at different concentrations at various HDAC subtypes. This resulted in the PROTAC (32a) (HI31.1) that degrades HDAC8 with a DC50 of 8.9 nM with a proper margin of selectivity against other isozymes. Moreover, PROTAC 32a is able to degrade HDAC6 with DC50 = 14.3 nM. Apoptotic study on leukemic cells (MV-4-11) displayed more than 50 % apoptosis took place at 100 nM. PROTAC 32a (HI31.1) showed a good margin of safety against normal cell line and proper chemical stability.

Light-Activatable Photochemically Targeting Chimeras (PHOTACs) Enable the Optical Control of Targeted Protein Degradation of HDAC6

PHOTACs enable optical control of protein degradation

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Light-induced Control of Protein Destruction by Opto-Protac.

Light-Induced Protein Degradation With Photocaged Protacs

Development of Visible-Light-activatable Photocaged PROTACs

Probing class I histone deacetylases (HDAC) with proteolysis targeting chimera (PROTAC) for the development of highly potent and selective degraders

Advances in the Design and Development of PROTAC-mediated HDAC degradation.

Cell-Specific Degradation of Histone Deacetylase Using Warhead-Caged Proteolysis Targeting Chimeras

Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery

Photo-regulated PROTACs: A novel tool for temporal control of targeted protein degradation

Development and characterization of the first selective class IIb histone deacetylase degraders

PhotoPROTACs: A Novel Biotechnology for Cancer Treatment

Plasticity in Designing PROTACs for Selective and Potent Degradation of HDAC6

Development of the First-in-Class FEM1B-Recruiting Histone Deacetylase Degraders

DNA-templated spatially controlled proteolysis targeting chimeras for CyclinD1-CDK4/6 complex protein degradation

Hydrogen Peroxide-Inducible PROTACs for Targeted Protein Degradation in Cancer Cells

Photoswitchable PROTACs for Reversible and Spatiotemporal Regulation of NAMPT and NAD+

A Photoactivatable Upconverting Nanodevice Boosts the Lysosomal Escape of PROTAC Degraders for Enhanced Combination Therapy

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Precise Modulation of Protein Degradation by Smart PROTACs